Form 8-K - Current report:
SEC Accession No. 0001654954-25-010510
Filing Date
2025-09-09
Accepted
2025-09-09 08:02:08
Documents
15
Period of Report
2025-09-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tennx_8k.htm   iXBRL 8-K 25266
2 AMENDMENT TO THE LICENSE AGREEMENT tennx_ex101.htm EX-10.1 49357
  Complete submission text file 0001654954-25-010510.txt   198244

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tennx-20250903.xsd EX-101.SCH 5045
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tennx-20250903_lab.xml EX-101.LAB 14667
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tennx-20250903_cal.xml EX-101.CAL 911
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tennx-20250903_pre.xml EX-101.PRE 9288
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tennx-20250903_def.xml EX-101.DEF 2112
17 EXTRACTED XBRL INSTANCE DOCUMENT tennx_8k_htm.xml XML 3911
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 251301705
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)